Antiverse Raises $9.3M Series A To Advance AI Antibody Platform

Treating diseases linked to so-called “undruggable” molecular targets remains a major challenge in medicine, with clinical candidate attrition rates around 90%.

Antiverse addresses this by using an AI-driven platform to generate therapeutic antibodies against complex targets such as G-protein coupled receptors (GPCRs) and ion channels, implicated in cancer, neurological disorders and rare genetic diseases like cystic fibrosis.

Read Also - Delphyr Raises €1.75 Million To Give Healthcare Professionals Time Back With AI

The company combines machine learning with in-house laboratory validation to design, build, and test antibody candidates in proprietary cell systems that mimic how target proteins appear in the human body. Promising candidates are then advanced toward clinical development.

Antiverse has partnered with the Cystic Fibrosis Foundation to design antibodies targeting the extracellular region of the CFTR protein, a historically challenging target using its AI platform to accelerate discovery.

The new funding will scale Antiverse’s AI-powered antibody discovery platform for pharmaceutical and foundation collaborations, expand its internal drug pipeline and advance lead candidates toward in vivo efficacy studies.

About Antiverse

Antiverse is a Welsh techbio company focused on designing therapeutic antibodies for challenging drug targets like GPCRs and ion channels. By combining AI-driven discovery with laboratory validation the company develops enabling technologies that accelerate the creation of novel therapies, helping bring transformative treatments to patients and improve lives.